Liquid Mine, Inc.

Liquid Mine (株式会社Liquid Mine) is a University of Tokyo Institute of Medical Science (東大医科研) spinout developing tailor-made liquid biopsy systems for leukemia minimal residual disease (MRD) monitoring. Their flagship service, MyRD, uses whole-genome sequencing (WGS) to identify patient-specific driver mutations, then applies symptom-specific assays and digital PCR on serum-derived cell-free DNA to precisely track leukemia cell reduction, residual disease, and recurrence. The system integrates leukemia gene analysis, bespoke assay creation, and ongoing MRD monitoring to deliver precision medicine for individual leukemia patients, enabling optimal treatment decisions and improving outcomes.